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The review analyzes up-to-date knowledge on structure and biological functions of α-acid glycoprotein. A
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Introduction. Comprehensive analysis of molecular
mechanisms of developing pathological states is of
both theoretical and practical importance for creation
sensitive and specific diagnostics and search for new
medicines. Nowadays it is known that the majority of
pathological states are connected with the changes in
synthesis and posttranslational modifications of certain 
proteins, which received a common name of acute
phase proteins (APPs). One of the most well-known
APPs is α-acid glycoprotein (AGP), or orosomucoid –
an acute inflammation protein of all mammals. Despite
a significant number of studies, many issues remain
unclear, including structural and functional changes of
this glycoprotein during diseases.
This review generalises modern literature data on
AGP expression, peculiarities of its glycolysation at
the development of pathological states, and
perspectives of further investigation.
Structural Organisation of AGP. The only
polypeptide chain of orosomucoid consists of 181
amino acid residues and contains two disulfide bonds
between cysteine residues, namely Cys5-Cys147 and
Cys72-Cys164. At pH 7.4, a protein part of AGP
molecule contains 15% of α-helixes, 41% of β-sheets,
12% of β-helixes, and 24% of non-ordered structures.
The secondary and ternary structures of this protein are
foreseen by IR and Raman-spectroscopy. The protein is 
supposed to consist of eight antiparallel β-structures,
forming so called β-cylinder with hydrophobic pocket
in the middle, which participates in binding some
medicines due to the presence of three tryptophan
residues [1]. Nishi et al. in their experiments with
desialylated and restored AGP revealed a natural
tendency to form α-helixes while disulfide bonds are
intermediate links between β-sheet and α-helix
structures. Moreover, the absence of histidine residue
in position 172 prevents the formation of α-helixes and
the interaction between protein and biomembranes [2].
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The AGP structure is characterized by high level of
glycosylation, i.e. it contains five complex N-glycanes, 
which bind to asparagine residues and make up 41-45% 
of total molecular weight. AGP has a high negative
charge (pI=2.7-3.2) owing to significant content of
sialic acids (12%). The molecular weight of plasmatic
AGP, according to different authors, varies from 35-37
to 41-43 kDa and depends on the structure of carbonic
component and the place of synthesis [3]. For instance,
AGP secreted by activated neutrophils has a higher
molecular weight due to the fucosylation of its
glycanes and the presence of polylactoseamine
residues [4].
 Genetic polymorphism of desialylated AGP was
found by the method of isoelectrofocusing.
Polypeptide variants of AGP are encoded by three
neighbouring genes, AGP-A, AGP-B, AGP-B’, the
first and second being identical. These genes are
located in q31-q34.1 locus of the ninth human
chromosome and encode two molecular forms different 
in 21 out of 181 amino acid residues, AGP-1 having
four and AGP-2 five cysteine residues. It is not known
whether the additional fifth Cys149 residue plays any
role in the formation of disulfide bond in AGP-1
molecule. At normal conditions, AGP-1 exceeds
AGP-2 in human blood plasma by about three times,
but there are data that this ratio changes in different
pathological states [5]. The amino acid sequence and
location of introns in three genes demonstrate close
similarity of AGP with lipocalins and partial similarity
with a receptor of epithelial growth factor [6].
Synthesis and expression of AGP. AGP is
predominantly synthesised by hepatocytes, but its
unhepatic synthesis, including that in tumour tissues, is 
also known. Recently it has been shown that AGP can be 
synthesized by myelocytes and secreted by secondary
granules of polymorphonuclear neutrophils [4].
The AGP synthesis and glycolysation are
independently regulated by cytokines and
glucocorticoids. Lipopolysacharide (LPS) of
gramm-negative bacteria, some cytokines
(interleukine-1b, tumour necrosis α-factor, and
interleukine-6) and glucocorticoids are the inducers of
AGP synthesis. On the contrary, other cytokines
(interleukine-1ra, interleukine-4, interleukine-10 and
TGF-β) inhibit the synthesis of this protein [7].
The normal AGP content in blood is 0.55-1.4 g/l.
The AGP concentration in blood plasma of healthy
adults does not depend on age, but is defined by gender. 
The level of orosomucoid in blood plasma of men is
somewhat higher (0.81 g/l) than that of women (0.67
g/l), and AGP content varies throughout the menstrual
period [8, 9]. Embryonic orosomucoid is detected in
foetus blood during the 16th week of embryonic
development and constantly increases with gestational
aging. The AGP concentration in newborns is
0.25-0.93 g/l and increases with age reaching the level
of adults at 10 months [10].
During acute phase response, i.e. at] inflammation,
trauma, surgical intervention, malignant
transformation etc. the AGP level in blood plasma
increases 2-5-fold [11]. The increase in AGP content
was proven for HIV-infection [12]. According to this
research, high concentration of AGP prevents
intracellular accumulation of protease inhibitors in
vitro. Therefore, the binding of mentioned inhibitors to
AGP is supposed to play a significant role in the
decrease in antiviral activity, though the sites of their
binding in AGP molecule are yet to be defined.
A new trend in AGP study has been recently
developed. It has been proven that the increase in AGP
level in urine is an early marker of dysfunction of
endothelium under the conditions of diabetic
nephropathy and cardiac complications [13]. It is
believed to be the consequence of disorder in
proangiogenic properties of this glycoprotein [14].
Biological role of AGP. The variety of AGP
biological functions has not been yet studied
completely, however, participation of AGP in
regulation of immune reactions, protection from
bacterial infections, maintaining the barrier for
transendothelial transport of macromolecules, and
inhibition of cell apoptosis has been shown. The
moment of its occurrence in blood as well as a
significant affinity to main substances allow
considering this glycoprotein to be an
immunomodulator, binding endo- and exogenic
mediators of inflammation. Together with
retinol-binding protein and α-1-microglobulin, AGP is
a member of the family of immunocalins, subfamily of
lipocalins, modulating immune and inflammatory
reactions. It is also notable for the ability to protect an
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organism under conditions of excess production of
inflammatory cytokines, in particular, at endotoxic
shock [15]. A protective activity of AGP was also
demonstrated in experiments with bacterial infection in 
mice [16].
Particular significance is attributed to the transport
properties of AGP. It was revealed that it is capable of
binding and transporting about 300 neutral and alkaline
substances of exo- and endogenic origin, the interaction
with medical preparations being dependent on human
genotype [17]. AGP in blood plasma is the main carrier
of positively charged medical substances and contains at 
least three binding sites for: 1) medical substances
(lipocalin “pocket”), 2) plasma proteins, and 3) receptors
of cell surface. It binds steroids (progesterone,
androstenedione, and cortisol) and anion ligands
(warfarin, phenobarbital, and retinol), as well as
serotonin, melatonin, histamine, and factor of activation
of thrombocytes. Pregnant women and newborns
demonstrate weakening in AGP interaction with medical
substances, which results in higher than expected level of
“free” fractions of medical substances [6, 11].
Glycosylation of AGP under normal conditions.
AGP is present in blood in several molecular forms,
identical in primary sequence of polypeptide part, but
different in biological activity and composition of
carbohydrate chains, which determines
microheterogeneity of this protein. The AGP
concentration and ratio of its glycoforms depend on the 
age, physiological condition of a person and change
during acute and chronic inflammation and tumour
formation [8]. Up till now a complete sequences of five
desialylated N-glycans of human AGP have been
described and the sites of their binding to the
polypeptide chain have been determined [18].
N-glycans of AGP belong to a “complex type”: they
contain the links gal-glcNAc, joined to the general
central area, which consists of two residues of
α-manose, one residue of β-manose and one residue of
chitobiose. One residue of α-manose, bound to C-3
residue of β-manose, has antennas at C-2 and C-4,
while the second - at C-2 and C-6 (Fig.1). The reason of 
such asymmetry is the substrate specificity of different
N-acetylglucosaminyltransferases, responsible for
binding during the formation of chain of each
N-acetylglucosamine residue to the preceding chain. It
is noteworthy that N-acetylglucosamine with a
separation function was not found in the AGP
composition. Another notable feature of N-glycans of
AGP appeared to be the presence of fucose which binds 
to the residue of N-acetylglucosamine via α1-3 or
α1-4-bond (Fig.1, b).
Five N-glycans of orosomucoid are different in the
degree of branching, sialylation and fucosylation. It is
known that AGP, containing bi-, tri- and tetra-antenna
N-glycans, is synthesized at normal conditions (Fig.1,
a). Sialic acids, occupying terminal positions in
orosomucoid molecule, may be in two isomeric forms:
α-2,3-bound residues of sialic acids, which are most
frequently expressed at tri- and tetra-antenna glycans,
and α-2,6-bound residues, expressed at biantennary
glycans. Considerable increase in branching and
sialylation of orosomucoid glycans is observed during
pregnancy [9].
It is noteworthy that foetal AGP is completely
different from the AGP of adults. It has three
N-glycans of lacto- and polylacto- substituted types
and three O-glycans, which are absent in AGP from
other tissues [10].
Structural and functional changes in AGP at
inflammation. Early stage of acute phase is
characterized by a considerable increase in the number
of AGP glycoforms with biantennary glycans, which
reaches its maximum on the 2nd day with subsequent
decreasing to the control level between 15 and 30 days.
Acute inflammation also causes significant changes in
AGP fucosylation with kinetics different from that for
biantennary glycans. In all the investigated patients
with heavy burn and accident injuries the fucosylation
level was still increased on the 10th-30th day, while the 
content of biantennary glycans reached a normal value
within 9-14 days after hospitalization [19].
During the acute phase of inflammation the number 
of fucosylated AGP molecules and fucose residues per
each molecule of the mentioned glycoprotein increases
(Fig.2), which is in good agreement with the
experimental data regarding changes in expression of
sialyl-Lewis antigens (SLeA and SLeX) at
inflammation. Sialylated Lewis antigens are
insignificant in AGP of a healthy adult, but their level
increases considerably at acute and chronic
inflammatory processes [20]. It is believed to be related 
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to the increase in hepatic synthesis of such AGP
glycoforms under the influence of inflammatory
cytokines [21]. AGP may inhibit classic and alternative 
ways of activation of the complement, and the increase
in SLeX-antigens in AGP composition enhances such
effects considerably. The expression of SLeX during
acute inflammation affects AGP affinity to E- or
P-selectins which, in its turn, results in the increase of
leukocytes in the places of inflammation [22].
The increase in the content of SLeX-antigens is
notable for tri - and tetra-antenna glycans which
correlates with the data on specificity of glycosylation
enzymes. It is known that α2-6-sialyltransferase has a
weak ability of sialylating N-glycans with tri - and
tetra-antenna structures compared to biantennary
structures. On the contrary, α2-3-sialyltransferase and
α1-3-fucosyltransferase, which are responsible for the
expression of SLeX-antigens, demonstrate enhanced
affinity to more branched glycans. It was also proven
that there is a positive correlation between the level of
branching of N-glycans and the activity of
α1-4-fucosyltransferase, responsible for the
SLeA-antigens synthesis [23]. Therefore, both the
changes in activity of abovementioned enzymes,
induced by inflammation, and the changes in the level
of branching of glycans may determine the expression
of Lewis-antigens in AGP composition.
Structural and functional changes in AGP at
malignization. The Table presents main trends in
structural changes of AGP at different pathological
states, including oncological diseases. It is known that
neoplastic processes are related to hypersecretion of
AGP, but the source of this protein is yet to be
elucidated. The paradox is the absence of changes in
AGP concentration in blood at hepatocellular
carcinoma, though in the patients with active forms of
lung cancer and cancer of gastrointestinal system a
considerable increase in AGP concentration is found.
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Fig. 1. Structural variants of
N-glycans of α1-acid glycoprotein:
a – bi-, tri- and tetra-antenna
N-glycans; b – in the presence of
fucose, bound to the residue of
N-acetyl glucosamine via α1-3- or 
α1-4-connection. Keys: gal –
galactose; man – manose; fuc –
fucose; glcNAc –
N-acetylglucosamine; *→ – NeuAc
(N-acetylneuraminic acid); Asn –
→galβ1→4glcNAcβ1→2manα1
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The level of AGP is an objective prognostic factor of
survival for patients with non-small-cell lung cancer: at 
AGP concentration less than 1.11 g/l average patient’s
life duration is 15.6 months, while at the concentration
of 1.85 g/l and more it is only 5.5 months [35]. There
are experimental data proving that AGP in high
concentration activates cell proliferation decreasing
the efficiency of tyrosine kinase inhibitor [36].
The data on changing AGP carbohydrate
component at neoplasia are limited to the investigation
on N-glycans] branching, sialylation and fucosylation.
A characteristic feature of oncological disease is a
higher] content of polyantenna glycans due to the
increase in expression of 1,4- and 1,6-branched tri - and 
tetra-antenna structures. Similar regularity was also
determined in our investigations on AGP structure in
patients with leukaemia or tumours of
pancreatoduodenal zone [27]. These patients
demonstrate considerable decrease in the amount of
biantennary glycans and proportional increase in the
amount of tri- and tetra-antenna structures in AGP
molecules, circulating in blood. It should be mentioned
that at mechanic jaundice, caused by oncological
diseases, there is a sharp decrease in the amount of
biantennary structures almost to their complete
disappearance [34].
It is known that tumour tissue secretes many
fucosylated proteins, including those with Lewis
antigens [37]. The increase in expression of SLeX- or
SLeA-antigens in neoplastic cells results in their
selectin-mediated extravasation and is closely related
to the cell migration and tumour metastases. “Deep”
fucosylation may be a factor, preventing adhesion and
affecting the formation of metastases. According to
[38], the patients with progressing malignization,
whose AGP contains highly fucosylated tri- and
tetra-antenna carbohydrate chains, had poor prognosis
during a long period after surgery, in contrast to the
patients who did not have such signs and prognosis for
whom was more favourable.
 The changes in expression and glycosylation of
AGP determine a variety of biological effects, some of
which are accomplished by the protein part, while
others mainly depend on its carbohydrate part.
A group of Russian scientists confirmed
immunomodulating activity of the glycan units [39].
They synthesized pseudo-AGP, which is similar to the
native AGP by the molecular weight and carbohydrate
units, attached to a to polymer carrier. Such
semi-synthetic analogue inhibits proliferation of
lymphocytes and stimulates the production of
anti-inflammatory cytokines by mononuclear
leukocytes of peripheral blood just like native AGP.
However, it neither affects antioxidant activity nor
prevents the complement activation in an alternative
way. Since the AGP doses used in these experiments
corresponded to the norm (<3 mg/ml), the authors
made an assumption that such non-specific activity of
AGP may be a cause of a tumour “escape” from
immune surveillance, thus preventing effect of
immunotherapy.
Therefore, an increased expression of α-1 acid
glycoprotein may be regarded as an adequate reaction
of the organism to any pathological process, being
non-specific for neoplasia; however, a high level of
AGP is likely relates to the disease progression.
“Subtle” changes, namely, changes in fucosylation,
sialylation and branching of AGP are more sensitive
and specific indicator of the development of
269
EXPRESSION AND STRUCTURAL-FUNCTIONAL ALTERATIONS OF α-1-ACID GLYCOPROTEIN
Fig. 2. Glycoforms of α1-acid glycoprotein, present in blood under
physiologically normal conditions (a), at acute (b) and chronic (c)
inflammation [15]. Stars indicate fucose.
a
b
c
AGP
AGP AGP
AGP
AGPAGP
pathological process. Further studies on
microheterogeneity of AGP are a promising direction
in the search for specific diagnostic markers and
development of therapeutic preparations with directed
immunomodulating activity.
Í. ². Ñòºêëºíüî âà, À. ². Øåâ öî âà, Î. Ç. Áðà çà ëóê, À. Î. Êóë³í³÷
Åêñïðåñ³ÿ ³ ñòðóê òóð íî-ôóíêö³îíàëüí³ çì³íè α-1-êèñ ëî ãî
ãë³êîï ðî òå¿ íó çà ïà òî ëîã³÷íèõ ñòàí³â
Ðå çþ ìå
Ïðî à íàë³çî âà íî ñó ÷àñí³ äàí³ ùîäî ñòðóê òó ðè ³ á³îëîã³÷íèõ
ôóíêö³é α-1-êèñ ëî ãî ãë³êîï ðî òå¿ íó. Îñîá ëè âó óâà ãó ïðèä³ëåíî
çì³í³ ôó êî çèëü î âà íîñò³, ñ³àëü î âà íîñò³ ³ ðîç ãà ëó æå íîñò³
ãë³êàí³â îðî çî ìó êî¿ äó çà ãîñ òðî ãî ³ õðîí³÷íî ãî çà ïà ëåí íÿ òà
îíêîò ðàí ñôîð ìàö³¿.
Êëþ ÷îâ³ ñëî âà: α-1-êèñ ëèé ãë³êîï ðî òå¿í, ãë³êî çèëü î âàí³ñòü,
çà ïà ëåí íÿ, îíêî ïà òî ëîã³ÿ.
Í. È. Ñòåê ëå íå âà, À. È. Øåâ öî âà, À. Ç. Áðà çà ëóê, À. À. Êó ëè íè÷ 
Ýêñïðåñ ñèÿ è ñòðóê òóð íî-ôóíê öè î íàëü íûå èç ìå íå íèÿ α-1-
êèñ ëî ãî ãëè êîï ðî òå è íà ïðè ïà òî ëî ãè ÷åñ êèõ ñî ñòî ÿ íè ÿõ
Ðå çþ ìå
Ïðî à íà ëè çè ðî âà íû ñî âðå ìåí íûå äàí íûå, êà ñà þ ùè å ñÿ ñòðóê -
òó ðû è áè î ëî ãè ÷åñ êèõ ôóí êöèé α-1-êèñ ëî ãî ãëè êîï ðî òå è íà.
Îñîáîå âíè ìà íèå óäå ëå íî èç ìå íå íèþ ôó êî çè ëè ðî âàí íîñ òè,
ñèà ëèðî âàí íîñ òè è ðàç âåò âëåí íîñ òè ãëè êà íîâ îðî çî ìó êî è äà
ïðè îñòðîì è õðî íè ÷åñ êîì âîñ ïà ëå íèè, à òàê æå îíêîò ðàíñ-
ôîð ìà öèè.
Êëþ ÷å âûå ñëî âà: α-1-êèñ ëûé ãëè êîï ðî òå èí, ãëè êî çè ëè ðî -
âàí íîñòü, âîñ ïà ëå íèå, îíêî ïà òî ëî ãèÿ.
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